These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

110 related items for PubMed ID: 9581839

  • 1. Vaccination with multiple antigen peptide as rejection antigen peptide in murine leukemia.
    Manki A, Ono T, Uenaka A, Seino Y, Nakayama E.
    Cancer Res; 1998 May 01; 58(9):1960-4. PubMed ID: 9581839
    [Abstract] [Full Text] [Related]

  • 2. Expression of multiple unique rejection antigens on murine leukemia BALB/c RLmale symbol1 and the role of dominant Akt antigen for tumor escape.
    Matsuo M, Wada H, Honda S, Tawara I, Uenaka A, Kanematsu T, Nakayama E.
    J Immunol; 1999 Jun 01; 162(11):6420-5. PubMed ID: 10352255
    [Abstract] [Full Text] [Related]

  • 3. Occurrence of tumor antigen pRL1a specific CD8 T cells in spleen cells from syngeneic BALB/c, semiallogeneic (BALB/c x C57BL/6)F1 and allogeneic C57BL/6 mice.
    Hata H, Uenaka A, Takada I, Kenjo A, Takahashi M, Ono T, Fujita T, Nakayama E.
    Int J Oncol; 2002 May 01; 20(5):1019-25. PubMed ID: 11956599
    [Abstract] [Full Text] [Related]

  • 4. Cellular processing of a multibranched lysine core with tumor antigen peptides and presentation of peptide epitopes recognized by cytotoxic T lymphocytes on antigen-presenting cells.
    Ota S, Ono T, Morita A, Uenaka A, Harada M, Nakayama E.
    Cancer Res; 2002 Mar 01; 62(5):1471-6. PubMed ID: 11888922
    [Abstract] [Full Text] [Related]

  • 5. Analysis of CD8 T-cell response by IFNgamma ELISPOT and H-2L(d)/pRL1a tetramer assays in pRL1a multiple antigen peptide-immunized and RL male 1-bearing BALB/c and (BALB/c x C57BL/6) F(1) mice.
    Takada I, Noguchi Y, Kenjo A, Wada H, Uenaka A, Fujita T, Inoue H, Nakayama E.
    Cancer Sci; 2004 Mar 01; 95(3):254-9. PubMed ID: 15016326
    [Abstract] [Full Text] [Related]

  • 6. Possible involvement of autoreactive CD4 T cells in generation of cytotoxic T lymphocytes on in vitro stimulation with H-2 class I-binding tumor antigen peptide.
    Honda S, Wada H, Uenaka A, Nakayama E.
    Int Immunol; 1998 Aug 01; 10(8):1167-74. PubMed ID: 9723703
    [Abstract] [Full Text] [Related]

  • 7. Diversity of epitopes recognized by cytotoxic T lymphocytes that are specific for rejection antigen peptide pRL1a presented on BALB/c leukemia RL Male 1.
    Yokoi T, Uenaka A, Ono T, Onizuka S, Inoue H, Nakayama E.
    Int Immunol; 1997 Aug 01; 9(8):1195-201. PubMed ID: 9263017
    [Abstract] [Full Text] [Related]

  • 8. Murine leukemia RL male 1 and sarcoma Meth A antigens recognized by cytotoxic T lymphocytes (CTL).
    Uenaka A, Nakayama E.
    Cancer Sci; 2003 Nov 01; 94(11):931-6. PubMed ID: 14611667
    [Abstract] [Full Text] [Related]

  • 9. Simian virus 40 large-T-antigen-specific rejection of mKSA tumor cells in BALB/c mice is critically dependent on both strictly tumor-associated, tumor-specific CD8(+) cytotoxic T lymphocytes and CD4(+) T helper cells.
    Utermöhlen O, Schulze-Garg C, Warnecke G, Gugel R, Löhler J, Deppert W.
    J Virol; 2001 Nov 01; 75(22):10593-602. PubMed ID: 11602701
    [Abstract] [Full Text] [Related]

  • 10. Requirement of CD4+ T cells and antigen-presenting cells for primary in vitro generation of CD8+ cytotoxic T cells against Ld-binding self-peptide p2Ca.
    Wada H, Ono T, Uenaka A, Monden M, Nakayama E.
    Immunology; 1995 Apr 01; 84(4):633-7. PubMed ID: 7790038
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Antitumor effects of systemic and local immunization with a CTL-directed peptide in combination with a local injection of OK-432.
    Ono T, Harada M, Yamada A, Tanaka M, Takao Y, Tanaka Y, Mine T, Sakamoto K, Nakashima T, Itoh K.
    Clin Cancer Res; 2006 Feb 15; 12(4):1325-32. PubMed ID: 16489090
    [Abstract] [Full Text] [Related]

  • 13. H-40, an antigen controlled by an Igh-linked gene and recognized by cytotoxic T lymphocytes. II. Recognition of H-40 as a tumor antigen in leukemic animals.
    Henderson LA, Ciavarra R, Riblet R, Forman J.
    J Immunol; 1984 Nov 15; 133(5):2778-85. PubMed ID: 6434638
    [Abstract] [Full Text] [Related]

  • 14. Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination.
    Maitre N, Brown JM, Demcheva M, Kelley JR, Lockett MA, Vournakis J, Cole DJ.
    Clin Cancer Res; 1999 May 15; 5(5):1173-82. PubMed ID: 10353754
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effector mechanisms of syngeneic anti-tumour responses in mice. II. Cytotoxic T lymphocytes mediate neutralization and rejection of radiation-induced leukaemia RL male 1 in the nude mouse system.
    Keyaki A, Kuribayashi K, Sakaguchi S, Masuda T, Yamashita J, Handa H, Nakayama E.
    Immunology; 1985 Sep 15; 56(1):141-51. PubMed ID: 3876272
    [Abstract] [Full Text] [Related]

  • 19. Identification of a CD4 T-cell epitope in tumor rejection antigen RLakt on BALB/c radiation-leukemia RL male 1.
    Kaya S, Uenaka A, Sato S, Ono T, Aji T, Nakayama E.
    Cancer Sci; 2008 Jul 15; 99(7):1441-7. PubMed ID: 18452555
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.